<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> Mar 2025 - Rilemo (ex. Previeni) ****completes a clinical staff survey with 250+ in person interviews to validate market need & define the long term strategy at the European Congress of Radiology (ECR25)
</aside>
Linkedin Post following the ECR2025 congress
<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> Dec 2024 - Rilemo (ex. Previeni) wins **€50.000,00 Grant Equity free from Fondazione UNIMI during Seed4Innovation
</aside>
IRCCS Galeazzi Linkedin Post Link
<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> Nov 2024 - Rilemo demonstrates fluid detection capability compared with a CT Scan in Hospital Settings with Bovine Animal ex-vivo samples
</aside>
Publication under writing. TBD in May ‘25. A confidential report is available under request
<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> Sep 2024 - Rilemo (ex. Previeni) enters into Bocconi 4 Innovation (B4i) Acceleration program securing a €50.000,00 investment and incorporating as Rilemo s.r.l.
</aside>
Bocconi 4 Innovation announcement Linkedin Post Link
<aside> <img src="/icons/arrow-left-basic_blue.svg" alt="/icons/arrow-left-basic_blue.svg" width="40px" /> Jul 2024 - Rilemo (ex. Previeni) wins €10.000,00 Grant Equity free during the Unfold AI competition by Dock3
</aside>
<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> Jun 2024 - Rilemo completes a USA and East Europe tour to analyse the market state and future expansion strategy
</aside>
East Europe Linkedin Post Link - USA Linkedin Post Link
<aside> <img src="/icons/arrow-left-basic_blue.svg" alt="/icons/arrow-left-basic_blue.svg" width="40px" /> May 2024 - Rilemo demonstrates fluid detection capability compared with a X-Ray in Clinical Settings with In-Vitro Synthetic samples based on real Human MRI Images
</aside>
Publication under evaluation. TBD in March ‘25. A confidential report is available under request
<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> Apr 2024 - Rilemo (ex. Previeni) and Avertis merge to join forces with their common vision of fighting late and wrong diagnoses, complementing the team
</aside>
<aside> <img src="/icons/arrow-left-basic_blue.svg" alt="/icons/arrow-left-basic_blue.svg" width="40px" /> Feb 2024 - Rilemo (ex. Previeni) & Avertis complete a User survey with 40+ in person interviews to validate market need & define the short term strategy at the European Congress of Radiology (ECR24)
</aside>
<aside> <img src="/icons/arrow-right-basic_blue.svg" alt="/icons/arrow-right-basic_blue.svg" width="40px" /> 2022 / 2023 - Rilemo (ex. Previeni) and Avertis win two successive Switch2Product Startup Challenge by PoliHub securing €30.000,00 in Grants
</aside>
<aside> <img src="/icons/arrow-left-basic_blue.svg" alt="/icons/arrow-left-basic_blue.svg" width="40px" /> Sep 2022 - after in-depth interviews with Medical Doctors, Rilemo pivots on portable diagnostics and starts miniaturisation to obtain the first, backpack sized, prototype
</aside>
